SpyGlass Pharma, Inc. (SGP)
NASDAQ: SGP · Real-Time Price · USD
26.68
+0.26 (0.98%)
At close: Mar 6, 2026, 4:00 PM EST
26.94
+0.26 (0.97%)
After-hours: Mar 6, 2026, 5:04 PM EST
Company Description
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions.
The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), which comprises novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients.
It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021.
The company was incorporated in 2019 and is based in Aliso Viejo, California.
SpyGlass Pharma, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 6, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Patrick Mooney |
Contact Details
Address: 27061 Aliso Creek Road, Suite 100 Aliso Viejo, California 92656 United States | |
| Phone | 949 284 6904 |
| Website | spyglasspharma.com |
Stock Details
| Ticker Symbol | SGP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001778922 |
| CUSIP Number | 85220G109 |
| ISIN Number | US85220G1094 |
| Employer ID | 83-3044245 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Patrick Mooney | Chief Executive Officer and Director |
| Malik Y. Kahook, M.D. | Co-founder, President, Chief Medical Officer, Executive Chair of the Board and Director |
| James Dennewill | Chief Operating Officer |
| Chetan Pujara, Ph.D. | Chief Research and Development Officer |
| Jean-Frédéric Viret, Ph.D. | Chief Financial Officer |
| Glenn Sussman | Co-founder and Chief Technology Advisor |
| Ali Behbahani, M.D. | Director |
| Michael Dybbs, Ph.D. | Director |
| Bilal Khan | Director |
| Kirk Nielsen | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Feb 17, 2026 | SCHEDULE 13D | Filing |
| Feb 13, 2026 | SCHEDULE 13D | Filing |
| Feb 13, 2026 | SCHEDULE 13D | Filing |
| Feb 13, 2026 | 8-K | Current Report |
| Feb 13, 2026 | SCHEDULE 13G | Filing |
| Feb 10, 2026 | SCHEDULE 13D | Filing |
| Feb 9, 2026 | 8-K | Current Report |
| Feb 6, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 6, 2026 | 424B4 | Prospectus |